SCHEMBL2275282

SCHEMBL2275282

COc1ccc(-c2cnc3[nH]cc(C(=O)NN4CCCC4)c3n2)cc1OC

nearest known ligand 0.65

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SYK P43405 3/20 0.65
CYP2C9 P11712 1/20 0.59
MAP4K1 Q92918 1/20 0.52
JAK2 O60674 2/20 0.48
JAK1 P23458 2/20 0.48
JAK3 P52333 2/20 0.48
AAK1 Q2M2I8 4/20 0.46
NOS1 P29475 1/20 0.46
STK17B O94768 3/20 0.44
STK17A Q9UEE5 1/20 0.44
MAP3K11 Q16584 3/20 0.43
KCNH2 Q12809 1/20 0.43
NEK2 P51955 1/20 0.43
KMT2A Q03164 1/20 0.43
CNR1 P21554 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2279906 0.99 SYK (0.64) SYKCYP2C9MAP4K1JAK2JAK1
Hydrochloric Acid SCHEMBL2275150 0.99 SYK (0.64) SYKCYP2C9MAP4K1JAK2JAK1
SCHEMBL2279041 0.85 SYK (0.83) SYKCYP2C9MAP4K1JAK2JAK1
SCHEMBL2279703 0.82 SYK (0.65) SYKCYP2C9MAP4K1JAK2JAK1
SCHEMBL2282760 0.82 SYK (0.69) SYKCYP2C9MAP4K1AAK1MAP3K11
SCHEMBL2276549 0.82 SYK (0.69) SYKCYP2C9MAP4K1JAK2JAK1
SCHEMBL2279702 0.82 SYK (0.69) SYKCYP2C9KCNH2
SCHEMBL2279046 0.80 SYK (0.69) SYKCYP2C9MAP4K1JAK2JAK1
SCHEMBL2276397 0.80 SYK (0.59) SYKCYP2C9MAP4K1JAK2JAK1
SCHEMBL2276876 0.80 SYK (0.59) SYKCYP2C9MAP4K1JAK2JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2245033-B1 PYRROLOPYRAZINE KINASE INHIBITORS HOFFMANN LA ROCHE (CH) 2011-08-31 EP claimed
US-8008298-B2 Pyrrolopyrazine kinase inhibitors Roche Palo Alto (US) 2011-08-30 US claimed
EP-2245033-A1 PYRROLOPYRAZINE KINASE INHIBITORS F. Hoffmann-La Roche AG (CH) 2010-11-03 EP claimed
US-20100267666-A1 Pyrrolopyrazine kinase inhibitors ROCHE PALO ALTO LLC 2010-10-21 US claimed
WO-2009106441-A1 PYRROLOPYRAZINE KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2009-09-03 WO claimed
EP-2245033-B1 PYRROLOPYRAZINE KINASE INHIBITORS HOFFMANN LA ROCHE (CH) 2011-08-31 EP disclosed
US-8008298-B2 Pyrrolopyrazine kinase inhibitors Roche Palo Alto (US) 2011-08-30 US disclosed
US-20100267666-A1 Pyrrolopyrazine kinase inhibitors ROCHE PALO ALTO LLC 2010-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267666-A1 Pyrrolopyrazine kinase inhibitors SYK, ZAP70, TYK2 SYK 1/4885CYP2C9 3511/4885MAP4K1 462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.